Compare FedEx Corporation (FDX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Summit Therapeutics Inc — how do they compare? FedEx Corporation trades at $291.71 (market cap $69.04B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: FedEx Corporation is far larger — about 5× Summit Therapeutics Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Summit Therapeutics Inc for 16 Days on average.
| FDX | SMMT | |
|---|---|---|
Market Cap | $69.04B | $13.71B |
Volume | 1,287,367 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $339.35 | $26.38 |
52-Week Low | $180.87 | $12.43 |
Typical Hold Time | 87 Days | 16 Days |
Enterprise Value | $98.68B | $13.04B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 15.73 and net income margin of 4.68%, though revenue has declined from $93.5B in 2022 to $87.9B in 2025. Recent developments include a $300 million electric truck order and strong shareholder support for management.
Wall Street remains bullish with a $307.55 consensus target (57% buy ratings), but rising fuel costs and competitive pressures pose risks. The stock offers value pricing with P/S of 0.74 and positive cash flow projection for 2026, though technical indicators suggest near-term resistance around $294-299.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
